ArticleNature2024
Targetable leukaemia dependency on noncanonical PI3Kγ signalling.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Glioma microenvironment: Cellular crosstalk, immunosuppression, and novel therapeutic perspectives.Chinese medical journal · 2026Review
- CRISPR application in hematological disorders: from bench to bedside.Blood advances · 2026Review
- Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.Science translational medicine · 2026Article
- Fungal metabolite-based immunotherapy overcomes tumor-associated macrophage immunosuppression.Cell reports. Medicine · 2026Article
- A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026Review
- Inhibition of Histone Lactylation by Dichloromethane Extract From Patrinia scabiosaefolia Fisch on Acute Myeloid Leukemia Cells.Chemistry & biodiversity · 2026Article
- Mapping functional non-coding variation in individual human genomes through haplotyping, multiomics, and deep learning.Nature communications · 2026Article
- Fatty acid scavenging enables cancer escape from KRAS inhibition.bioRxiv : the preprint server for biology · 2026Article
- Exploiting tumor lineage features for precision cancer therapy.Trends in cancer · 2026Review
- Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.Journal of translational medicine · 2026Review
- Hypoxia-driven tumor immune escape: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
- A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies.Cell communication and signaling : CCS · 2025Article
- AKR1B1 is Required for Maintaining Acute Leukemia Cell Survival by Epigenetic Silencing of Tumor Suppressor Genes.Biochemical genetics · 2025Article
- The impact of PANoptosis-related genes on immune profiles and subtype classification in ischemic stroke.Scientific reports · 2025Article
- Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem Cells.bioRxiv : the preprint server for biology · 2025Article
- Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia.Biomedicines · 2025Review
- Danshenol B alleviates central post-stroke pain by regulating the PIK3CG/NLRP3 signaling pathway.Journal of translational medicine · 2025Article
- Targeting PI3Kγ in cancer.Trends in cancer · 2025Review
- A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer.Nature communications · 2025Article
- Molecular principles underlying aggressive cancers.Signal transduction and targeted therapy · 2025Review
Corrections and comments
- Commented on by
- Update of
Authors and funding
16 authors.
Qingyu LuoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4164-637X
Evangeline G RaulstonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Miguel A PradoInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.ORCID 0000-0002-4914-1619
Xiaowei WuDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-4176-7198
Kira GritsmanDepartment of Medical Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.
Karley S WhalenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Kezhi YanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Christopher A G BoothDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3841-6637
Ran XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-5023-3281
Peter van GalenDivision of Hematology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-0735-1570
John G DoenchGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-3707-9889
Shai ShimonyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7245-9652
Henry W LongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6849-6629
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2566-3145
Joao A PauloDepartment of Cell Biology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4291-413X
Andrew A LaneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. andrew_lane@dfci.harvard.edu.ORCID 0000-0001-7380-0226
Funding
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)R37CA225191 · NCI · DANA-FARBER CANCER INST · PI LANE, ANDREW A · 2018 to 2024
$3.0MPI3K Isoform Dependence in Adult Hematopoiesis and Myeloid LeukemiaR01CA196973 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GRITSMAN, KIRA · 2016 to 2020
$2.0MNCI NIH HHS R01 CA196973NCI NIH HHS R37 CA225191
Abstract
Phosphoinositide-3-kinase-γ (PI3Kγ) is implicated as a target to repolarize tumour-associated macrophages and promote antitumour immune responses in solid cancers
Indexed as
Class Ib Phosphatidylinositol 3-KinaseLeukemiap21-Activated KinasesSignal TransductionAnimalsCell LineCytarabineHumansMiceMitochondriaOxidative PhosphorylationPhosphorylationrac1 GTP-Binding ProteinXenograft Model Antitumor AssaysClass Ib Phosphatidylinositol 3-KinaseCytarabinep21-Activated KinasesPAK1 protein, humanPIK3CG protein, humanrac1 GTP-Binding ProteinRAC1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.